Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 6, 2007, Pages 559-564

  Lincz, Lisa F ^a,b,c   Adams, Murray J ^d   Scorgie, Fiona E ^a,c   Thom, Jim ^e   Baker, Ross I ^e   Seldon, Michael ^a,c,f  

^a NEWCASTLE MATER HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f HUNTER NEW ENGLAND HEALTH   (Australia)

Author keywords

Antiphospholipid syndrome; Factor V Leiden; Tissue factor pathway inhibitor; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ALLELE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASSAY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ACTIVITY; FEMALE; GENOTYPE; HUMAN; HYPERCOAGULABILITY; HYPOTHESIS; INHERITANCE; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ADULT; ANTIPHOSPHOLIPID SYNDROME; FACTOR V; HUMANS; LIPOPROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; VENOUS THROMBOSIS;

EID: 34548364003     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3281eec977     Document Type: Article

References (35)

1. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263:6001-6004.
2. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995; 6 (Suppl 1):S7-S13.
3. Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 1998; 102:889-895.
4. He M, Wen Z, He X, Xiong S, Liu F, Xu J, et al. Observation on tissue factor pathway and some other coagulation parameters during the onset of acute cerebrocardiac thrombotic diseases. Thromb Res 2002; 107:223-228.
5. Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariens RA. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001; 113:537-543.
6. Adams MJ, Donohoe S, Mackie IJ, Machin SJ. Antitissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. Br J Haematol 2001; 114:375-379.
7. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208:327-339.
8. Almasy L, Soria JM, Souto JC, Warren DM, Buil A, Borrell M, et al. A locus on chromosome 2 influences levels of tissue factor pathway inhibitor: results from the GAIT study. Arterioscler Thromb Vasc Biol 2005; 25:1489-1492.
9. Arnaud E, Moatti D, Emmerich J, Aiach M, de Prost D. No link between the TFPI V264M mutation and venous thromboembolic disease. Thromb Haemost 1999; 82:159-160.
10. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309-1311.
11. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.
12. Roubey RA. Immunology of the antiphospholipid syndrome: antibodies, antigens, and autoimmune response. Thromb Haemost 1999; 82:656-661.
13. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
14. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344:1222-1231.
15. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004; 140:330-337.
16. Hoke M, Kyrle PA, Minar E, Bialonzcyk C, Hirschl M, Schneider B, et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005; 94:787-790.
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
18. Moatti D, Haidar B, Fumeron F, Gauci L, Boudvillain O, Seknadji P, et al. A new T-287C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haemost 2000; 84:244-249.
19. Moatti D, Seknadji P, Galand C, Poirier O, Fumeron F, Desprez S, et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol 1999; 19:862-869.
20. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991; 2:425-433.
21. Ameziane N, Seguin C, Borgel D, Fumeron F, Moatti D, Alhenc-Gelas M, et al. The -33T->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. Thromb Haemost 2002; 88:195-199.
22. Miyata T, Sakata T, Kumeda K, Uchida K, Tsushima M, Fujimura H, et al. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis. Thromb Haemost 1998; 80:345-346.
23. Moatti D, Meirhaeghe A, Ollivier V, Bauters C, Amouyel P, de Prost D. Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty. Blood Coagul Fibrinolysis 2001; 12:317-323.
24. Akarsu M, Demirkan F, Ozsan GH, Onen F, Yuksel F, Ozkan S, et al. Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behcet's disease. Am J Hematol 2001; 68:225-230.
25. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79:276-281.
26. Wakita Y, Wada H, Nakase T, Nakasaki T, Shimura M, Hiyoyama K, et al. Aberrations of the tissue factor pathway in patients positive for lupus anticoagulant. Clin Appl Thromb Hemost 1999; 5:10-15.
27. Kiraz S, Ertenli I, Benekli M, Haznedaroglu IC, Calguneri M, Celik I, et al. Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 1999; 8:737-741.
28. Adams M, Breckler L, Stevens P, Thom J, Baker R, Oostryck R. Antitissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation. Haematologica 2004; 89:985-990.
29. Eitzman DT, Westrick RJ, Bi X, Manning SL, Wilkinson JE, Broze GJ, et al. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 2002; 105:2139-2142.
30. van 't Veer C, Kalafatis M, Bertina RM, Simioni P, Mann KG. Increased tissue factor-initiated prothrombin activation as a result of the Arg506 -> Gln mutation in factor VLEIDEN. J Biol Chem 1997; 272:20721-20729.
31. Hubbard AR, Weller LJ, Gray E. Measurement of tissue factor pathway inhibitor in normal and postheparin plasma. Blood Coagul Fibrinolysis 1994; 5:819-823.
32. Jeske W, Hoppensteadt D, Fareed J, Bermes E. Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations. Blood Coagul Fibrinolysis 1995; 6 (Suppl 1): S73-S80.
33. Adams MJ, Oostryck R. A comparative study of functional assays for tissue factor pathway inhibitor using normal plasma and clinical samples. Blood Coagul Fibrinolysis 2000; 11:327-333.
34. Bognacki J, Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1995; 6 (Suppl 1):S65-S72.
35. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86:959-972.